Difference between revisions of "Part:BBa K2624000:Design"
Zhoushuyao (Talk | contribs) (→References) |
Zhoushuyao (Talk | contribs) |
||
| Line 8: | Line 8: | ||
===Design Notes=== | ===Design Notes=== | ||
Somatic mutations in the promoter of the gene for human telomerase reverse transcriptase (hTERT) are the most common noncoding mutations in cancer. Our design of this hTERT promoter (-146C>T, -138C>T, -139C>T) is according to such documented mutations. | Somatic mutations in the promoter of the gene for human telomerase reverse transcriptase (hTERT) are the most common noncoding mutations in cancer. Our design of this hTERT promoter (-146C>T, -138C>T, -139C>T) is according to such documented mutations. | ||
| − | |||
| − | |||
| − | |||
===Source=== | ===Source=== | ||
Latest revision as of 13:49, 22 August 2018
hTERT promoter
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Design Notes
Somatic mutations in the promoter of the gene for human telomerase reverse transcriptase (hTERT) are the most common noncoding mutations in cancer. Our design of this hTERT promoter (-146C>T, -138C>T, -139C>T) is according to such documented mutations.
Source
GenBank nucleotide sequence database, with mutations.
References
[1]Liu T, Yuan X, Xu D. Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications:[J]. Genes, 2016, 7(7):38.
[2]Zhuang C L, Fu X, Liu L, et al. Synthetic miRNA sponges driven by mutant hTERT promoter selectively inhibit the progression of bladder cancer.[J]. Tumor Biology, 2015, 36(7):5157.
[3]Heidenreich B, Nagore E, Rachakonda PS, et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma[J]. Nature communications, 2014, 5(2):3401.
[4]Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells[J]. Cancer research, 1999, 59(3): 551-557.